ClinicalTrials.gg
Not yet recruitingNCT07937787Updated Nov 16, 2026

A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

A Phase 1 interventional study of QLS2406-1 injection and Placebo in Overweight and Obesity and MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.

Read the detailed description

This study is the first-in-human (FIH) trial of QLS2406-1 injection, a randomized, double-blind, placebo-controlled Phase I clinical study consisting of two parts.

Part A is a single ascending dose (SAD) design with doses escalated sequentially per the predefined escalation scheme. Eight overweight or obese participants will be enrolled in each cohort and randomized at a 6:2 ratio to receive QLS2406-1 or placebo. Part B is a multiple ascending dose (MAD) study in obese participants. Two dosing frequencies are to be explored: once weekly (QW), and once every two weeks (Q2W). For the QW schedule, 15 obese participants will be randomized at a 12:3 ratio to receive QLS2406-1 or placebo. For the Q2W schedule, 12 participants will be randomized at a 10:2 ratio to receive QLS2406-1 or placebo.

The primary objective is to evaluate the safety and tolerability of this new long-acting quad-agonist QLS2406-1. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate if the long-acting four-receptor agonist has possible pharmacodynamic effects measured as changes in weight, waist circumference and lipid profiles.

02

Conditions studied

  • Overweight and Obesity
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

03

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's planned enrollment of 124 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD is the lead sponsor of 8 studies on the registry; 8 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A

    1. Aged 18 to 55 years (inclusive) at screening, with no restriction on gender;
    2. At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive);
    3. Subjects are in good health as comprehensively assessed by the Investigator, with no abnormalities on physical examination, vital signs, 12-lead (ECG), abdominal ultrasonography, clinical laboratory tests, etc.;
    4. Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy.
    5. Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written
  • Part B

    1. Aged 18 to 65 years (inclusive) at screening, regardless of gender;
    2. BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive);
    3. Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy;
    4. Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent;
    5. Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported).

Exclusion criteria

Exclusion Criteria:

  1. Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications;
  2. History of any severe clinical disease, or cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or within 24 weeks prior to randomization;
  3. Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc.;
  4. Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study;
  5. Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology;
  6. History of hypoglycemia within 24 weeks prior to randomization;
  7. 12-lead at screening with heart rate >100 bpm or \<50 bpm, second- or third-degree atrioventricular block, prolonged (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome;
  8. History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg;
  9. Use of any drugs, products or non-pharmacologic therapies (other than product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening;
  10. Any screening laboratory value meeting any of the following criteria, including but not limited to:

    • Serum amylase or serum lipase >1.5 × (ULN);
    • Fasting glucose abnormality or (HbA1c) ≥6.5%;
    • Calcitonin >20 ng/L;
    • TG ≥5.65 mmol/L (500 mg/dL);
    • E value ≥12.0 kPa (FibroScan) (Part B only)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Part A Cohort 1

    SAD dose 1

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part A Cohort 2

    SAD dose 2

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part A Cohort 3

    SAD dose 3

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part A Cohort 4

    SAD dose 4

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part A Cohort 5

    SAD dose 5

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 1

    MAD dose 1

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 2

    MAD dose 2

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 3

    MAD dose 3

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 4

    MAD dose 4

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 5

    MAD dose 5

    Drug: QLS2406-1 injection · Drug: Placebo

  • Experimental
    Part B Cohort 6

    MAD dose 6

    Drug: QLS2406-1 injection · Drug: Placebo

Interventions

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered as a single dose via subcutaneous injection.

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered as a single dose via subcutaneous injection.

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered as a single dose via subcutaneous injection.

  • DrugQLS2406-1 injection

    Administered subcutaneously

  • DrugPlacebo

    Placebo will be administered as a single dose via subcutaneous injection.

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered as a single dose via subcutaneous injection.

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

  • DrugQLS2406-1 injection

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    A summary of AEs, SAEs, and other non-serious adverse events following single subcutaneous injection of QLS2406-1

    Time frame: Baseline to Day 71

Secondary outcomes

  1. Cmax of QLS2406-1

    Maximum observed plasma concentration of QLS2406-1

    Time frame: From baseline to the end of treatment (up to Day 71)

  2. AUC of QLS2406-1

    Area under the serum concentration-time curve (AUC)

    Time frame: From baseline to the end of treatment (up to Day 71)

  3. Tmax of QLS2406-1

    Evaluate the time to reach peak plasma concentration of QLS2406-1

    Time frame: From baseline to the end of treatment (up to Day 71)

  4. Half-life of QLS2406-1

    Evaluate the time required for the plasma concentration of QLS2406-1 to decrease by 50%

    Time frame: From baseline to the end of treatment (up to Day 71)

  5. % Change From Baseline in Body Weight

    Weight

    Time frame: From baseline to the end of treatment (up to Day 71)

  6. % Change From Baseline in Fasting Lipid Concentration

    Fasting lipid concentration

    Time frame: From baseline to the end of treatment (up to Day 71)

  7. Incidence of Anti-drug Antibodies (ADA)

    Assessment of the incidence of anti-drug antibodies (ADA) developed against QLS2406-1 after dosing

    Time frame: From baseline to the end of treatment (up to Day 71)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937787
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

qian zhang, Master of Medicine
Contact
Zhangqian@ahmu.edu.com
86-0551-65997163

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion